Skip to main content

Matthew Plavan

Equibles does not estimate personal net worth.

About Matthew Plavan

Matthew Plavan was last confirmed as CEO and Board Member at Arcadia Biosciences, Inc. (RKDA) in a filing dated April 20, 2021. The proxy statement of Arcadia Biosciences, Inc. reports total compensation of $1,606,004 for Matthew Plavan in fiscal 2021, including a base salary of $443,998. Disclosed compensation is on record for 4 fiscal years. Matthew Plavan has spoken on 2 earnings calls across 1 company, most recently for Arcadia Biosciences, Inc. on November 12, 2020. The companies whose calls Matthew Plavan spoke on are classified in the Consumer Defensive sector.

Matthew Plavan on recent calls

“Since our last call, I'm pleased to report Arcadia achieved a number of fundamental milestones, resulting in a more focused execution strategy, and a tangibly strengthened financial ability to achieve our number one goal to drive near-term shareholder value by unlocking the full potential of our commercially ready…”
CEO, Arcadia Biosciences, Inc. Q3 FY2020 Earnings Call ·
“With me today at safe distances are Pam Haley, our Chief Financial Officer and Sarah Reiter, our Chief Commercial Officer. I want to open by saying that I hope all of you listening in today as well as your families and your loved ones are staying safe and healthy.”
CEO, Arcadia Biosciences, Inc. Q1 FY2020 Earnings Call ·

Affiliation history

Company network

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2021 Arcadia Biosciences, Inc. (RKDA) $443,998 $1,606,004
2020 Arcadia Biosciences, Inc. (RKDA) $370,000 $794,148
2019 Arcadia Biosciences, Inc. (RKDA) $321,538 $581,078
2018 Arcadia Biosciences, Inc. (RKDA) $289,618 $583,010

Recent activity